Precipio, Inc. (PRPO): Price and Financial Metrics


Precipio, Inc. (PRPO): $0.78

0.02 (+2.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRPO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PRPO Stock Summary

  • With a market capitalization of $17,115,195, PRECIPIO INC has a greater market value than only 5.91% of US stocks.
  • Of note is the ratio of PRECIPIO INC's sales and general administrative expense to its total operating expenses; 86.94% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 104.65%, PRECIPIO INC's debt growth rate surpasses 88.2% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PRECIPIO INC are AIRS, WRBY, NRDY, ONEM, and EVR.
  • Visit PRPO's SEC page to see the company's official filings. To visit the company's web site, go to www.precipiodx.com.

PRPO Valuation Summary

  • In comparison to the median Healthcare stock, PRPO's price/sales ratio is 5% lower, now standing at 1.9.
  • Over the past 243 months, PRPO's EV/EBIT ratio has gone up 3.6.

Below are key valuation metrics over time for PRPO.

Stock Date P/S P/B P/E EV/EBIT
PRPO 2022-11-25 1.9 1 -1.4 -1.1
PRPO 2022-11-23 1.9 1 -1.4 -1.1
PRPO 2022-11-22 1.8 1 -1.4 -1.1
PRPO 2022-11-21 1.9 1 -1.5 -1.2
PRPO 2022-11-18 1.9 1 -1.5 -1.2
PRPO 2022-11-17 1.9 1 -1.5 -1.2

PRPO Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 2120.86%.
  • Its 4 year revenue growth rate is now at 133.14%.
  • The year over year net cashflow from operations growth rate now stands at -6.84%.
Over the past 33 months, PRPO's revenue has gone up $6,329,000.

The table below shows PRPO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 9.456 -7.621 -12.118
2022-06-30 9.487 -7.509 -10.799
2022-03-31 9.472 -7.622 -11.668
2021-12-31 8.849 -6.577 -8.53
2021-09-30 8.355 -6.628 -8.194
2021-06-30 7.736 -6.92 -9.636

PRPO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRPO has a Quality Grade of D, ranking ahead of 7.61% of graded US stocks.
  • PRPO's asset turnover comes in at 0.324 -- ranking 58th of 76 Measuring and Control Equipment stocks.
  • ROP, AXDX, and TMO are the stocks whose asset turnover ratios are most correlated with PRPO.

The table below shows PRPO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.324 0.268 19.897
2021-03-31 0.331 0.223 15.583
2020-12-31 0.307 0.189 14.223
2020-09-30 0.247 0.135 15.678
2020-06-30 0.200 0.076 11.555
2020-03-31 0.174 0.084 12.523

PRPO Price Target

For more insight on analysts targets of PRPO, see our PRPO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.5 (Moderate Buy)

PRPO Stock Price Chart Interactive Chart >

Price chart for PRPO

PRPO Price/Volume Stats

Current price $0.78 52-week high $2.12
Prev. close $0.76 52-week low $0.74
Day low $0.76 Volume 23,000
Day high $0.78 Avg. volume 170,926
50-day MA $0.82 Dividend yield N/A
200-day MA $1.11 Market Cap 17.73M

Precipio, Inc. (PRPO) Company Bio


Precipio, Inc. operates as a biotechnology company. The Company offers medicines for oncology, cardiology, neurology, and inherited diseases. Precipio also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Precipio serves customers in the United States.


PRPO Latest News Stream


Event/Time News Detail
Loading, please wait...

PRPO Latest Social Stream


Loading social stream, please wait...

View Full PRPO Social Stream

Latest PRPO News From Around the Web

Below are the latest news stories about PRECIPIO INC that investors may wish to consider to help them evaluate PRPO as an investment opportunity.

Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference

Poster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen™ MPN AssayNEW HAVEN, Conn., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted in collaboration with faculty at the University of Pennsylvania. The study, expected to be published in detail early next year, demonstrates the

Yahoo | November 7, 2022

Precipio Announces Third Quarter Shareholder Update Call

Conference Call to be held on Monday, November 14th, 2022 at 5:00 PM ETNEW HAVEN, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2022 shareholder update call on Monday, November 14th at 5:00 PM ET. The call will include updates on the Company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio

Yahoo | November 2, 2022

Precipio, Inc. (NASDAQ:PRPO) Is Expected To Breakeven In The Near Future

With the business potentially at an important milestone, we thought we'd take a closer look at Precipio, Inc.'s...

Yahoo | October 18, 2022

Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™

Adding customer segment exceeding $100M in market potentialNEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy). Following an upcoming training program and onboarding of their national coverage, this distribution channel partner’s sales team will begin promoting and driving sales of the HemeScreen platform

Yahoo | September 15, 2022

Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales

Precipio continues to build strong team in anticipation of substantial growth in the next 12 monthsNEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Sharon Robins as the Company’s Senior Director of Laboratory & Hospital Sales for the Product’s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (a

Yahoo | August 24, 2022

Read More 'PRPO' Stories Here

PRPO Price Returns

1-mo -7.14%
3-mo N/A
6-mo -33.33%
1-year -55.68%
3-year -62.32%
5-year -95.74%
YTD -50.63%
2021 -23.67%
2020 0.98%
2019 -8.89%
2018 -87.50%
2017 -85.71%

Continue Researching PRPO

Want to see what other sources are saying about Precipio Inc's financials and stock price? Try the links below:

Precipio Inc (PRPO) Stock Price | Nasdaq
Precipio Inc (PRPO) Stock Quote, History and News - Yahoo Finance
Precipio Inc (PRPO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5829 seconds.